follow becn result provid follow key takeaway well
pre-cal bullet bodi note overal despit sale ep
expect well januari organ sale grow yoy
contrast declin reiter sale ebitda ep
guidanc given still earli stage year specif regard result
sale growth roughli in-lin estim price bp
price/cost continu posit third consecut quarter addit
gross margin solidli bp yoy driven
roughli bp posit price/cost rest posit mix synergi
alli acquisit howev adjust sg well
bp sequenti bp yoy oper expens
impact histor season compani continu work
acquisit integr lastli importantli view rsa model roll-out
note go quit well modestli rais ep ebitda
million respect million follow
compani modestli better result stronger januari organ growth trend
howev slightli lower ep ebitda million
respect million becom slightli conserv
oper margin expans bp yoy vs bp prior lastli
rais dec price target base
target multipl roughli ebitda roughli half turn
current valuat ebitda given compani
current elev leverag continu rate neutral believ
current valuat trade roughli ebitda appropri
reflect compani temporari elev leverag recent challeng well
solid long-term track record term acquisit integr core growth
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
guidanc revenu adjust ebitda ep maintain despit
sale expect fantast gross margin result ep
estim maintain sale ebitda ep
guidanc given still earli stage year specif sale expect
billion assum roughli flat organ growth midpoint
driven expect organ growth initi includ open new
branch posit carryov price increas estim impact
roughli off-set mid single-digit volum declin due still tough weather
comp still benefit storm activ tx co
benefit fl hurrican irma notabl low end revenu
guidanc assum softer econom demand environ high end
assum return normal storm demand overal major weather
event assum adjust ebitda guidanc also maintain
million continu impli ebitda margin
midpoint bp expans yoy lower end ebitda rang base
lower end revenu rang well weaker gross margin stem
competit backdrop weaker demand environ also
remain track achiev full annual run rate million synergi
target roughli million lastli compani updat rang
depreci million million prior maintain rang
interest expens million amort million stock
compens million free cash flow million adjust ep
sale growth roughli in-lin estim exceed becn
expect price/cost remain posit third straight quarter januari
organ growth sale solid follow declin sale grew
organ roughli in-lin organ flat estim
compani expect residenti sale rose organ roughli in-lin
organ flat estim complementari rose organ
roughli in-lin organ estim non-residenti rose
organ in-lin organ flat estim region organ sale
continu impact difficult comp soft hailstorm activ west
volum yoy non-western divis serv partial off-set
good organ growth month sale improv throughout quarter
stabil organ net sale trend moreov januari saw solid organ
growth rang well price roughli continu track similar
exit rate price quarter bp gain across product
categori similar bp benefit price increas prior price increas
continu flow new price increas implement
quarter importantli note posit price outpac cost inflat third
gross margin solidli bp yoy
gross margin bp sequenti bp yoy
solidli drive yoy improv roughli bp
benefit posit mix synergi alli acquisit well bp
higher margin legaci busi led posit price/cost well benefit
compani strateg initi includ product procur custom price
modestli adjust ep adjust ebitda well
rais dec price target maintain neutral rate
modestli rais ep ebitda million respect
million follow compani modestli better result
stronger januari organ growth trend howev slightli lower ep
ebitda million respect million
becom slightli conserv oper margin expans
bp yoy vs bp prior lastli rais dec price target
base target multipl roughli ebitda
roughli half turn current valuat ebitda
given compani current elev leverag continu rate neutral
believ current valuat trade roughli ebitda
appropri reflect compani temporari elev leverag recent
challeng well solid long-term track record term acquisit
integr core growth
take expect modestli posit reaction stock tomorrow
adjust ebitda ep slightli street moreov
compani reiter guidanc amid still challeng earn guidanc
season lastli call note januari organ sale grew yoy
contrast declin
result summari report adjust ebitda million
modestli street million in-lin million estim
similarli adjust ep modestli street
upsid ep estim driven adjust gross margin
vs drove upsid lower interest expens
drove upsid partial off-set higher adjust sg
drove downsid lastli compani maintain
guidanc sale adjust ebitda adjust ep
revenu adjust ebitda adjust ep guidanc reiter
guidanc reiter across key metric includ sale
billion adjust ebitda million impli bp margin
expans yoy midpoint adjust ep
consolid sale rose slightli organ
flat estim segment residenti roof sale rose slightli
organ flat estim commerci roof sale rose
in-lin organ flat estim
complementari build product sale rose in-lin organ
oper margin ex-charg slightli
gross margin bp sequenti bp yoy solidli
drive yoy improv roughli bp posit
price/cost compani realiz bp price quarter rest
posit mix synergi mostli alli acquisit howev adjust
sg well bp sequenti bp
yoy result oper margin ex-charg slightli
bp sequenti bp yoy
invest thesi valuat risk
trade roughli ebitda believ becn valuat
appropri reflect temporarili elev leverag recent challeng
surround sale consist guidanc well upsid potenti next
two year alli integr compani organ growth initi
addit opportun lastli beacon repres defens name
within build product univers view driven stabl end
market result rate neutral
rais dec price target base
roughli target ev/ebitda multipl ebitda
roughli half turn stock multipl ebitda
believ target multipl appropri roughli half turn stock current
multipl driven addit leverag took quarter purchas
futur tax benefit fund work capit maintain overal free cash
flow leverag target ex- addit leverag stock trade
ebitda believ appropri reflect becn recent challeng
well long-term track record regard integr acquisit core
risk rate price
believ follow risk could drive rel
outperformance/underperform henc repres risk neutral rate
first price could improve/deterior drive potenti upside/downsid
revenu growth gross margin second sale mix could positively/neg
impact gross margin shift away/toward non-residenti sale third
futur acquisit may accelerate/deceler due market condit
beacon roof suppli summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end sep o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover also certifi per kofia requir analysi made good faith
view reflect opinion without undu influenc intervent
